EDP Sciences logo
Authentification abonné
rechercher
Menu
Accueil Tous les numéros Volume 70 / Numéro 2 (Mars-Avril 2015) Therapie, 70 2 (2015) 213-221 Références
Numéro
Therapie
Volume 70, Numéro 2, Mars-Avril 2015
Addictovigilance : le défi pharmacologique de l'évaluation et de la prévention des substances à risque
Page(s) 213 - 221
Section Addictovigilance / Addictovigilance
DOI https://doi.org/10.2515/therapie/2015014
Publié en ligne 9 avril 2015
  1. Micaleff J, Jolliet P, Victorri-Vigneau, et al. Premières journées nationales de pharmacodépendance (CEIP). Place de la pharmacodépendance dans l’évaluation du médicament. Therapie 2008; 63: 55-65 [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  2. Gillen C, Haurand M, Kobelt DJ, et al. Affinity, potency and efficacy of tramadol and its metabolites at the cloned human µ-opioid receptor. Nauny-Schmiedebergs Arch Pharmacol 2000; 362: 116-21 [Google Scholar]
  3. Raffa RB. Basic pharmacology relevant to drug abuse assessment: tramadol as example. J Clin Pharm Ther 2008; 33: 101-8 [CrossRef] [PubMed] [Google Scholar]
  4. Epstein DH, Preston KL, Jasinski DR. Abuse liability, behavioural pharmacology, and physical-dependence potential of opioids in Humans and laboratory animals: lessons from tramadol. Psychol 2006; 73: 90-9 [Google Scholar]
  5. Trente-troisième rapport du comité OMS d’experts de la pharmacodépendance, Genève, 2003 http://apps.who.int/medicinedocs/pdf/s4897f/s4897f.pdf Accessed November 21st, 2014 (34 pages) [Google Scholar]
  6. Trente-quatrième rapport du comité OMS d’experts de la pharmacodépendance, Genève, 2006 http://apps.who.int/medicinedocs/documents/s14097f/s14097f.pdf Accessed November 21st, 2014 (36 pages) [Google Scholar]
  7. Boeuf O, Lapeyre-Mestre M, French Network of Centers for Evaluation and Information Pharmacodependence (CEIP). Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France: results of OSIAP survey. Drug Saf 2007; 30: 265-76 [CrossRef] [PubMed] [Google Scholar]
  8. Agence Nationale de Sécurité du Médicament et des produits de santé. Centres d’Évaluation et d’Information sur la Pharmacodépendance (CEIP). OSIAP (ordonnances suspectes, indicateur d’abus possible). Résultats de l’enquête 2012 http://ansm.sante.fr/var/ansm_site/storage/original/application/ccf1b031de966fdc90fae91647ab8461.pdf Accessed November 21st, 2014 (5 pages) [Google Scholar]
  9. Lapeyre-Mestre M, Gony M, Carvajal A, et al. A European community pharmacy-based survey to investigate patterns of prescription fraud through identification of falsified prescriptions. Eur Adict Res 2014; 20: 174-82 [Google Scholar]
  10. Thirion X, Micallef J, Barrau K, et al. Observation of psychoactive substance consumption: methods and results of the French OPPIDUM programme. Eur Addict Res 2001; 7: 32-6 [CrossRef] [PubMed] [Google Scholar]
  11. Micallef-Roll J, Lapeyre-Mestre M, Association française des CEIP-Addictovigilance. Second meeting of the French CEIP (Centres d’évaluation et d’information sur la pharmacodépendance). Part I: how to evaluate and prevent the abuse and dependence on hypnotic/anxiolytic drugs? Therapie 2009; 64: 355-64 [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  12. Frauger E, Moracchini C, Le Boisselier R, et al. OPPIDUM surveillance program: 20 years of information on drug abuse in France. Fundam Clin Pharmacol 2013; 27: 672-82 [CrossRef] [PubMed] [Google Scholar]
  13. Moracchini C, Orleans V, Miloudi S, et al. General practitioners’ contribution to dependence assessment: the OPEMA programme. Therapie 2012; 67: 397-404 [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  14. Clarot F, Goullé JP, Vaz E, et al. Fatal overdoses of tramadol: is benzodiazepine a risk factor of lethality? Forensic Sci Int 2003; 134: 57-61 [CrossRef] [PubMed] [Google Scholar]
  15. Tjäderborn M, Jönsson AK, Hägg S, et al. Fatal unintentional intoxications with tramadol during 1995-2005. Forensic Sci Int 2007; 173: 107-11 [CrossRef] [PubMed] [Google Scholar]
  16. Orriols L, Gaillard J, Lapeyre-Mestre M, et al. Evaluation of abuse and dependence on drugs used for self-medication: a pharmacoepidemiological pilot study based on community pharmacies in France. Drug Saf 2009; 32: 859-73 [CrossRef] [PubMed] [Google Scholar]
  17. American Psychiatric Association. DSM-IV-TR: Diagnostic and statistical manual of mental disorders, 4th ed, text revision. Washington DC: American Psychiatric Association. 2000 [Google Scholar]
  18. Sees KL, Clark HW. Opioid use in the treatment of chronic pain: assessment of addiction. J Pain Symptom Manage 1993; 8: 257-64 [CrossRef] [PubMed] [Google Scholar]
  19. Savage SR. Assessment for addiction in pain-treatment settings. Clin J Pain 2002; 18: S28-38 [CrossRef] [PubMed] [Google Scholar]
  20. Portenoy RK. Appropriate use of opioids for persistent non-cancer pain. Lancet 2004; 364: 739-40 [CrossRef] [PubMed] [Google Scholar]
  21. Agence Nationale de Sécurité du Médicament et des produits de santé. Comité Technique de Pharmacovigilance. Paris. 2013 http://ansm.sante.fr/var/ansm_site/storage/original/application/47860dababd65356aee23a7c82974954.pdf Accessed November 21st, 2014 (19 pages) [Google Scholar]
  22. Nazarzadeh M, Bidel Z, Carson KV. The association between tramadol hydrochloride misuse and other substances use in an adolescent population: phase I of a prospective survey. Addict Behav 2014; 39: 333-7 [CrossRef] [PubMed] [Google Scholar]
  23. Zosel A, Bartelson BB, Bailey E, et al. Characterization of adolescent prescription drug abuse and misuse using the Researched Abuse Diversion and Addiction-related Surveillance (RADARS®) System. J Am Acad Child Adolesc Psychiatry 2013; 52: 196-204 [CrossRef] [PubMed] [Google Scholar]
  24. Iravani FS, Akhgari M, Jokar F, et al. Current trends in tramadol-related fatalities, Tehran, Iran, 2005-2008. Subst Use Misuse 2010; 45: 2162-71 [CrossRef] [PubMed] [Google Scholar]
  25. Mayor S. Drug experts call for stronger regulation of tramadol to reduce misuse. BMJ 2013; 346: f1264 [CrossRef] [PubMed] [Google Scholar]
  26. Advisory Council of the Misuse of Drugs, February 2013 https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/144116/advice-tramadol.pdf Accessed November 21st, 2014 (20 pages) [Google Scholar]
  27. Senay EC, Adams EH, Geller A, et al. Physical dependence on Ultram (tramadol hydrochloride): both opioid-like and atypical withdrawal symptoms occur. Drug Alcohol Depend 2003; 69: 233-41 [CrossRef] [PubMed] [Google Scholar]
  28. Pradel V, Thirion X, Ronfle E, et al. Assessment of doctor-shopping for high dosage buprenorphine maintenance treatment in a French region: development of a new method for prescription database. Pharmacoepidemiol Drug Saf 2004; 13: 473-81 [CrossRef] [PubMed] [Google Scholar]
  29. Nordmann S, Pradel V, Lapeyre-Mestre M, et al. Doctor shopping reveals geographical variations in opioid abuse. Pain Physician 2013; 16: 89-100 [PubMed] [Google Scholar]
  30. Nordmann S, Frauger E, Pauly V, et al. Les systèmes d’évaluation de l’abus et de la dépendance des médicaments psychoactifs. Therapie 2011; 66: 263-72 [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  31. Pradel V, Frauger E, Thirion X, et al. Impact of a prescription monitoring program on doctor-shopping for high dosage buprenorphine. Pharmacoepidemiol Drug Saf 2009; 18: 36-43 [CrossRef] [PubMed] [Google Scholar]
  32. Canadian Pain Society. Review of abuse risk for tramadol. 2007 http://www.canadianpainsociety.ca/Tramadol/Tramadol_AbuseRisk_2006.pdf Accessed November 21st, 2014 (108 pages) [Google Scholar]